TriangleNCT05397171 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Full Range
- Time frame
- First dose until documented disease progression or study end (1 Year)
What was measured
The PFS was defined as the time from the start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from study intervention or received another anti-cancer therapy prior to progression. This outcome measure was assessed only for substudy 1 Part A.
Analysis population: Safety set included all participants who received any amount of IP.
Groups in this outcome
AZD8853 300 mg
Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
AZD8853 1000 mg
Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
AZD8853 3000 mg
Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
| Group | Source count |
|---|---|
| AZD8853 300 mg | 3 |
| AZD8853 1000 mg | 6 |
| AZD8853 3000 mg | 7 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| AZD8853 300 mg | 1.31 | Not reported | 1.18 | 3.38 | Not reported |
| AZD8853 1000 mg | 1.23 | Not reported | 1.15 | 3.15 | Not reported |
| AZD8853 3000 mg | 1.25 | Not reported | 0.95 | 3.29 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.18
- upper Limit
- 3.38
- value
- 1.31
- group Id
- OG001
- lower Limit
- 1.15
- upper Limit
- 3.15
- value
- 1.23
- group Id
- OG002
- lower Limit
- 0.95
- upper Limit
- 3.29
- value
- 1.25
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 7
- units
- Participants
- description
- The PFS was defined as the time from the start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from study intervention or received another anti-cancer therapy prior to progression. This outcome measure was assessed only for substudy 1 Part A.
- dispersion Type
- Full Range
- groups
- description
- Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG000
- title
- AZD8853 300 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG001
- title
- AZD8853 1000 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG002
- title
- AZD8853 3000 mg
- param Type
- MEDIAN
- population Description
- Safety set included all participants who received any amount of IP.
- reporting Status
- POSTED
- time Frame
- First dose until documented disease progression or study end (1 Year)
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice